<DOC>
	<DOCNO>NCT00393939</DOCNO>
	<brief_summary>This phase 3 randomize trial evaluate anti-tumor activity safety sunitinib combine docetaxel versus docetaxel , administer first-line treatment , patient unresectable locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Breast cancer evidence unresectable locally recurrent , metastatic disease Her2 negative tumor Patients docetaxel contraindicate Clinical presentation inflammatory carcinoma measurable disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Phase 3</keyword>
</DOC>